title: Impaired hemoglobin scavenging during an acute HIV-1 retroviral syndrome.
abstract: BACKGROUND
  We report a case of temporary impaired hemoglobin scavenging in a patient with an acute HIV-1 retroviral syndrome. The patient was presented at the emergency department in a severe inflammatory state, mimicking bacterial sepsis and/or hemophagocytic syndrome. The serum showed a hemolytic aspect. In contrast, serum haptoglobin concentration was not decreased.
  
  
  METHODS
  The hemolysis index was determined and the visual absorbance spectroscopy spectrum of the serum was studied. alpha1 microglobulin and hemopexin concentrations were determined in serum. The presence of circulating hemoglobin:haptoglobin complexes in serum and the saturation of the haptoglobin were investigated using starch gel electrophoresis followed by peroxidase staining. CD163 expression on peripheral blood monocytes was analyzed using flow cytometry.
  
  
  RESULTS
  A temporarily impaired hemoglobin scavenging was documented by an increased hemolysis index, absence of decreased haptoglobin levels, presence of circulating hemoglobin:haptoglobin complexes in serum and decreased hemopexin and alpha1 microglobulin concentrations.
  
  
  CONCLUSIONS
  A temporarily impaired hemoglobin scavenging was observed due to a transient CD163 pathway impairment following an acute HIV-1 retroviral syndrome. The patient improved clinically and biochemically after initiation of HIV-1 anti-retroviral therapy. The data suggest a transient HIV-1 mediated CD163 impairment, although a latent drug mediated block could not be ruled out completely.
authors.affiliation: Ghent University Hospital, Belgium. Joris.delanghe@ugent.be
authors.forename: Joris R
authors.initials: JR
authors.lastname: Delanghe
authors.forename: Jan
authors.initials: J
authors.lastname: Philippé
authors.forename: Filip
authors.initials: F
authors.lastname: Moerman
authors.forename: Marc L
authors.initials: ML
authors.lastname: De Buyzere
authors.forename: Liesbeth L
authors.initials: LL
authors.lastname: Vynckier
authors.forename: Alain G
authors.initials: AG
authors.lastname: Verstraete
authors.forename: Dirk P
authors.initials: DP
authors.lastname: Vogelaers
authors.forename: Linos
authors.initials: L
authors.lastname: Vandekerckhove
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology; D006242:Haptoglobins / Q000032:analysis / Q000378:metabolism*; D006454:Hemoglobins / Q000032:analysis / Q000378:metabolism*; D006461:Hemolysis; D006801:Humans; D008297:Male; D011956:Receptors, Cell Surface / Q000276:immunology; D013577:Syndrome; D055815:Young Adult; D000098902:CD163 Antigen
chemical_list: D019380:Anti-HIV Agents; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000098902:CD163 Antigen; D006242:Haptoglobins; D006454:Hemoglobins; D011956:Receptors, Cell Surface